世界の循環腫瘍細胞（CTC）予後技術市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z1341 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、循環腫瘍細胞（CTC）予後技術のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（腫瘍細胞濃縮、腫瘍細胞検出）、用途別市場規模（前立腺がん、乳がん、結腸直腸がん、肺がん、卵巣がん、膵臓がん）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・循環腫瘍細胞（CTC）予後技術の市場動向 ・企業の競争状況、市場シェア ・循環腫瘍細胞（CTC）予後技術の種類別市場規模（腫瘍細胞濃縮、腫瘍細胞検出） ・循環腫瘍細胞（CTC）予後技術の用途別市場規模（前立腺がん、乳がん、結腸直腸がん、肺がん、卵巣がん、膵臓がん） ・循環腫瘍細胞（CTC）予後技術の北米市場規模2016-2027（アメリカ、カナダ） ・循環腫瘍細胞（CTC）予後技術のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・循環腫瘍細胞（CTC）予後技術のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・循環腫瘍細胞（CTC）予後技術の中南米市場規模2016-2027（メキシコ、ブラジル） ・循環腫瘍細胞（CTC）予後技術の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AdnaGen、ACDBio、Celula、Epic Sciences、Fluxion Biosciences、Rarecells、Silicon Biosystems、Vitatex） ・結論

Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.

Market Analysis and Insights: Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is projected to reach US$ 3446.1 million by 2026, from US$ 1294.1 million in 2019, at a CAGR of 14.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market.

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Scope and Market Size
Circulating Tumor Cells (CTCs) Prognostic Technologies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Tumor Cell Enrichment
Tumor Cell Detection

Segment by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tumor Cell Enrichment
1.2.3 Tumor Cell Detection
1.3 Market by Application
1.3.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Lung Cancer
1.3.6 Ovarian Cancer
1.3.7 Pancreatic Cancer
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Perspective (2016-2027)
2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Growth Trends by Regions
2.2.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Share by Regions (2016-2021)
2.2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Regions (2022-2027)
2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Industry Dynamic
2.3.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Trends
2.3.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Drivers
2.3.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Challenges
2.3.4 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Revenue
3.1.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Revenue (2016-2021)
3.1.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Players (2016-2021)
3.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue
3.4 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio
3.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2020
3.5 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players Head office and Area Served
3.6 Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
3.7 Date of Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Type
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Type (2016-2021)
4.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Type (2022-2027)

5 Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Application
5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Application (2016-2021)
5.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2016-2027)
6.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type
6.2.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021)
6.2.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027)
6.2.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2027)
6.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application
6.3.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021)
6.3.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027)
6.3.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2027)
6.4 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country
6.4.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021)
6.4.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2016-2027)
7.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type
7.2.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021)
7.2.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027)
7.2.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2027)
7.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application
7.3.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021)
7.3.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027)
7.3.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2027)
7.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country
7.4.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021)
7.4.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2016-2027)
8.2 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type
8.2.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2027)
8.3 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application
8.3.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2027)
8.4 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region
8.4.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2016-2027)
9.2 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type
9.2.1 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021)
9.2.2 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027)
9.2.3 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2027)
9.3 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application
9.3.1 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021)
9.3.2 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027)
9.3.3 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2027)
9.4 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country
9.4.1 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021)
9.4.2 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2016-2027)
10.2 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type
10.2.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2027)
10.3 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application
10.3.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2027)
10.4 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country
10.4.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AdnaGen
11.1.1 AdnaGen Company Details
11.1.2 AdnaGen Business Overview
11.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.1.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.1.5 AdnaGen Recent Development
11.2 ACDBio
11.2.1 ACDBio Company Details
11.2.2 ACDBio Business Overview
11.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.2.4 ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.2.5 ACDBio Recent Development
11.3 Celula
11.3.1 Celula Company Details
11.3.2 Celula Business Overview
11.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.3.4 Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.3.5 Celula Recent Development
11.4 Epic Sciences
11.4.1 Epic Sciences Company Details
11.4.2 Epic Sciences Business Overview
11.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.4.4 Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.4.5 Epic Sciences Recent Development
11.5 Fluxion Biosciences
11.5.1 Fluxion Biosciences Company Details
11.5.2 Fluxion Biosciences Business Overview
11.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.5.4 Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.5.5 Fluxion Biosciences Recent Development
11.6 Rarecells
11.6.1 Rarecells Company Details
11.6.2 Rarecells Business Overview
11.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.6.4 Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.6.5 Rarecells Recent Development
11.7 Silicon Biosystems
11.7.1 Silicon Biosystems Company Details
11.7.2 Silicon Biosystems Business Overview
11.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.7.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.7.5 Silicon Biosystems Recent Development
11.8 Vitatex
11.8.1 Vitatex Company Details
11.8.2 Vitatex Business Overview
11.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.8.4 Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
11.8.5 Vitatex Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tumor Cell Enrichment
Table 3. Key Players of Tumor Cell Detection
Table 4. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions (2016-2021)
Table 8. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions (2022-2027)
Table 10. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Trends
Table 11. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Drivers
Table 12. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Challenges
Table 13. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Restraints
Table 14. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Players (2016-2021)
Table 16. Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies as of 2020)
Table 17. Ranking of Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
Table 21. Date of Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type (2016-2021)
Table 25. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Application (2016-2021)
Table 29. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2022-2027) & (US$ Million)
Table 61. AdnaGen Company Details
Table 62. AdnaGen Business Overview
Table 63. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Product
Table 64. AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 65. AdnaGen Recent Development
Table 66. ACDBio Company Details
Table 67. ACDBio Business Overview
Table 68. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Product
Table 69. ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 70. ACDBio Recent Development
Table 71. Celula Company Details
Table 72. Celula Business Overview
Table 73. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Product
Table 74. Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 75. Celula Recent Development
Table 76. Epic Sciences Company Details
Table 77. Epic Sciences Business Overview
Table 78. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Product
Table 79. Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 80. Epic Sciences Recent Development
Table 81. Fluxion Biosciences Company Details
Table 82. Fluxion Biosciences Business Overview
Table 83. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Product
Table 84. Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 85. Fluxion Biosciences Recent Development
Table 86. Rarecells Company Details
Table 87. Rarecells Business Overview
Table 88. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Product
Table 89. Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 90. Rarecells Recent Development
Table 91. Silicon Biosystems Company Details
Table 92. Silicon Biosystems Business Overview
Table 93. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Product
Table 94. Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 95. Silicon Biosystems Recent Development
Table 96. Vitatex Company Details
Table 97. Vitatex Business Overview
Table 98. Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021) & (US$ Million)
Table 99. Vitatex Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type: 2020 VS 2027
Figure 2. Tumor Cell Enrichment Features
Figure 3. Tumor Cell Detection Features
Figure 4. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application: 2020 VS 2027
Figure 5. Prostate Cancer Case Studies
Figure 6. Breast Cancer Case Studies
Figure 7. Colorectal Cancer Case Studies
Figure 8. Lung Cancer Case Studies
Figure 9. Ovarian Cancer Case Studies
Figure 10. Pancreatic Cancer Case Studies
Figure 11. Circulating Tumor Cells (CTCs) Prognostic Technologies Report Years Considered
Figure 12. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions: 2020 VS 2027
Figure 15. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions (2022-2027)
Figure 16. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Players in 2020
Figure 17. Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2020
Figure 19. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type (2016-2021)
Figure 20. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type (2022-2027)
Figure 21. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2016-2027)
Figure 23. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2016-2027)
Figure 24. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Country (2016-2027)
Figure 25. United States Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2016-2027)
Figure 29. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2016-2027)
Figure 30. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Country (2016-2027)
Figure 31. Germany Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Region (2016-2027)
Figure 41. China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2016-2027)
Figure 49. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2016-2027)
Figure 50. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Country (2016-2027)
Figure 51. Mexico Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Country (2016-2027)
Figure 57. Turkey Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. AdnaGen Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 61. ACDBio Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 62. Celula Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 63. Epic Sciences Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 64. Fluxion Biosciences Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 65. Rarecells Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 66. Silicon Biosystems Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 67. Vitatex Revenue Growth Rate in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---